Abstract 329P
Background
The first patient infected with the COVID-19 virus in Algeria was reported on February 25, 2020. Radiotherapy departments are potentially exposed like others to the COVID-19 pandemic and this is a crucial issue since cancer patients cannot interrupt their treatment. The objective of this study is to describe the different epidemiological and therapeutic aspects of patients treated with palliative radiotherapy at the time of COVD-19.
Methods
It is a prospective study of the files of 28 patients treated aimed palliative at the radiotherapy department of the cancer center Tlemcen, Algeria since the new guidelines of our department to contain the spread of the pandemic from March 19 to April 30.
Results
They are 19 men and 9 women (sex ratio 2.11) with a median age of 61 years (35-87). 13 patients (46.42%) had brain metastases, six patients (21.42%) had bone metastases, two patients (7.14%) had esophagus, two patients (7.14%) had maxillofacial metastases and five (17.87%) patients had other localizations (lung, thyroid, sarcoma, multiple myeloma and glioblastoma). 30GY protocol was delivered in six (21.42%) patients, 20GY protocol was delivered in 16 (57.14%) patients and 8GY protocol was delivered in five (17.87%) patients.11 cases (84.61%) of brain metastases were treated with 20GY, five cases (83.33%) of bone metastases were treated with 8GY. No cases were infected with the virus.
Conclusions
Palliative radiotherapy plays a critical role in preventing serious morbidity in cancer patients even in the midst of the current COVID-19 pandemic. The acute phase of the pandemic has led to major changes in radiotherapy treatment strategy, including the use of hypo-fractionated regimens for palliative radiotherapy, which are preferred to reduce patients' risk of exposure to COVID-19 and to limit treatment delays. Hypo fractionation is one option that could at least partially address these issues.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Mous.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
324P - COVID era: Perception of oncologists from a developing nation
Presenter: Rakesh Roy
Session: e-Poster Display Session
325P - Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines
Presenter: Frances Victoria Que
Session: e-Poster Display Session
326P - Management of diffuse large B cell lymphomas in the COVID-19 era
Presenter: David Ng
Session: e-Poster Display Session
327P - COVID-19 in patients with oncohematologic diseases in Kazakhstan
Presenter: Zaure Dushimova
Session: e-Poster Display Session
328P - Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
330P - COVID and cancer: Choosing between hammer and anvil
Presenter: Ullas Batra
Session: e-Poster Display Session
331P - The clock stopped with COVID-19 but continued ticking for cancer patients
Presenter: Sasi Shanmugam Senga
Session: e-Poster Display Session
336P - Efficacy of methylcobalamin administered intravenously for chemotherapy-induced peripheral neuropathy (CIPN): A prospective crossover study
Presenter: Jun Chen
Session: e-Poster Display Session
337P - A prospective study about the quality of life and chemotherapy-induced peripheral neuropathy
Presenter: Wala Ben Kridis
Session: e-Poster Display Session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session